Cationic dendritic starch as a vehicle for photodynamic therapy and siRNA co-delivery

Journal of Photochemistry and Photobiology B: Biology

Volumn 168, Issue , 2017, Pages 185-192

  Engelberth, Sarah A ^a   Hempel, Nadine ^b   Bergkvist, Magnus ^a  

^a SUNY POLYTECHNIC INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Cationic enzymatically synthesized glycogen; Co delivery; Photodynamic therapy; siRNA; Sulfonated porphyrin; TPPS

Indexed keywords

CATIONIC ENZYMATICALLY SYNTHESIZED GLYCOGEN; DRUG CARRIER; GLYCOGEN; MANGANESE SUPEROXIDE DISMUTASE; PHOTOSENSITIZING AGENT; SMALL INTERFERING RNA; TETRAPHENYLPORPHINESULFONIC ACID; UNCLASSIFIED DRUG; CATION; DENDRIMER; PORPHYRIN; STARCH; TETRAPHENYLPORPHINE SULFONATE;

ARTICLE; CELL DEATH; CELL SURFACE; CELL VIABILITY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; EPITHELIUM CELL; FEASIBILITY STUDY; FEMALE; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; ILLUMINATION; LIGHT EXPOSURE; MICROENCAPSULATION; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OVARY CELL; PARTICLE SIZE; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATIC ELECTRICITY; ZETA POTENTIAL; CHEMISTRY; COMBINATION DRUG THERAPY; DRUG EFFECTS; PHOTOCHEMOTHERAPY; PROCEDURES; TUMOR CELL CULTURE;

CATIONS; CELL DEATH; DENDRIMERS; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FEMALE; GLYCOGEN; HUMANS; PHOTOCHEMOTHERAPY; PORPHYRINS; RNA, SMALL INTERFERING; STARCH; TUMOR CELLS, CULTURED;

EID: 85013648542     PISSN: 10111344     EISSN: 18732682     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2017.02.013     Document Type: Article

References (39)

1. [1] Dougherty, T.J., Photodynamic therapy. Photochem. Photobiol. 58:6 (1993), 895–900.
2. [2] Nathan, T.R., et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J. Urol. 168:4 (2002), 1427–1432.
3. [3] Prosst, R., Wolfsen, H., Gahlen, J., Photodynamic therapy for esophageal diseases: a clinical update. Endoscopy 35:12 (2003), 1059–1068.
4. [4] Dilkes, M., et al. Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases. J. Laryngol. Otol. 117:9 (2003), 713–717.
5. [5] Bellnier, D.A., et al. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients. Cancer Res. 63:8 (2003), 1806–1813.
6. [6] Lorenz, K.J., Maier, H., Photodynamic therapy with meta-tetrahydroxyphenylchlorin (Foscan®) in the management of squamous cell carcinoma of the head and neck: experience with 35 patients. Eur. Arch. Otorhinolaryngol. 266:12 (2009), 1937–1944.
7. [7] Puolakkainen, P., Schröder, T., Photodynamic therapy of gastrointestinal tumors: a review. Dig. Dis. 10:1 (1992), 53–60.
8. [8] Moesta, K.T., et al. Evaluating the role of photodynamic therapy in the management of pancreatic cancer. Lasers Surg. Med. 16:1 (1995), 84–92.
9. [9] Kato, H., Photodynamic therapy for lung cancer—a review of 19 years’ experience. J. Photochem. Photobiol. B Biol. 42:2 (1998), 96–99.
10. [10] Baas, P., et al. Photodynamic therapy with meta-tetrahydroxyphenylchlorin for basal cell carcinoma: a phase I/II study. Br. J. Dermatol. 145:1 (2001), 75–78.
11. [11] Zeitouni, N.C., Oseroff, A.R., Shieh, S., Photodynamic therapy for nonmelanoma skin cancers: current review and update. Mol. Immunol. 39:17 (2003), 1133–1136.
12. [12] Schweitzer, V.G., Photofrin-mediated photodynamic therapy for treatment of aggressive head and neck Nonmelanomatous skin tumors in elderly patients. Laryngoscope 111:6 (2001), 1091–1098.
13. [13] Rhodes, L.E., et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch. Dermatol. 140:1 (2004), 17–23.
14. [14] Rechtman, E., et al. An update on photodynamic therapy in age-related macular degeneration. Expert Opin. Pharmacother. 3:7 (2002), 931–938.
15. [15] Müller, V.A., et al. Treatment of Rubeosis iridis with photodynamic therapy with Verteporfin–a new therapeutic and prophylactic option for patients with the risk of Neovascular glaucoma?. Ophthalmic Res. 35:1 (2003), 60–64.
16. [16] Szeimies, R., Landthaler, M., Karrer, S., Non-oncologic indications for ALA-PDT. Journal of Dermatological Treatment 13(sup1) (2002), S13–S18.
17. [17] Milla Sanabria, L., et al. Direct and indirect photodynamic therapy effects on the cellular and molecular components of the tumor microenvironment. Biochim. Biophys. Acta 1835:1 (2013), 36–45.
18. [18] Chen, W.H., et al. Nanoparticle delivery of HIF1alpha siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Cancer Lett. 359:1 (2015), 65–74.
19. [19] Lecaros, R.L., et al. Nanoparticle delivered VEGF-A siRNA enhances photodynamic therapy for head and neck cancer treatment. Mol. Ther. 24:1 (2016), 106–116.
20. [20] Schumann, C., et al. ROS-induced nanotherapeutic approach for ovarian cancer treatment based on the combinatorial effect of photodynamic therapy and DJ-1 gene suppression. Nanomedicine 11:8 (2015), 1961–1970.
21. [21] Miyake, M., et al. siRNA-mediated knockdown of the Heme synthesis and degradation pathways: modulation of treatment effect of 5-Aminolevulinic acid-based photodynamic therapy in Urothelial cancer cell lines. Photochem. Photobiol. 85 (2009), 1020–1027.
22. [22] Dong, D., et al. Therapeutic potential of targeted multifunctional nanocomplex co-delivery of siRNA and low-dose doxorubicin in breast cancer. Cancer Lett. 359:2 (2015), 178–186.
23. [23] Jin, G., et al. Multifunctional organic nanoparticles with aggregation-induced emission (AIE) characteristics for targeted photodynamic therapy and RNA interference therapy. Chem. Commun. (Camb.) 52:13 (2016), 2752–2755.
24. [24] Cogno, I.S., et al. Optimization of photodynamic therapy response by survivin gene knockdown in human metastatic breast cancer T47D cells. J. Photochem. Photobiol. B 104:3 (2011), 434–443.
25. [25] Engelberth, S.A., Hempel, N., Bergkvist, M., Chemically modified dendritic starch: a novel nanomaterial for siRNA delivery. Bioconjug. Chem. 26:8 (2015), 1766–1774.
26. [26] Kajiura, H., et al. A novel enzymatic process for glycogen production. Biocatal. Biotransformation 26:1–2 (2008), 133–140.
27. [27] Hemachandra, L.M.P., et al. Mitochondrial superoxide dismutase has a Protumorigenic role in ovarian clear cell carcinoma. Cancer Res. 75:22 (2015), 4973–4984.
28. [28] Chauvin, B., et al. Plasma distribution of tetraphenylporphyrin derivatives relevant for photodynamic therapy: importance and limits of hydrophobicity. Eur. J. Pharm. Biopharm. 83:2 (2013), 244–252.
29. [29] Kessel, D., et al. Tumor localization and photosensitization by Sulfonated derivatives of Tetraphenylporphine. Photochem. Photobiol. 45:6 (1987), 787–790.
30. [30] Winkelman, J., Collins, G., Neurotoxicity of tetraphenylporphinesulfonate TPPS4 and its relation to photodynamic therapy. Photochem. Photobiol. 46:5 (1987), 801–807.
31. [31] Sema, A., Experimental porphyric neuropathy: a preliminary report. Can. J. Neurol. Sci. 8 (1981), 105–114.
32. [32] Sortino, S., et al. Nanoparticles of cationic amphiphilic cyclodextrins entangling anionic porphyrins as carrier-sensitizer system in photodynamic cancer therapy. Biomaterials 27:23 (2006), 4256–4265.
33. [33] Kovaric, B., et al. Self-assembly of peptide porphyrin complexes: toward the development of smart biomaterials. J. Am. Chem. Soc. 128:13 (2006), 4166–4167.
34. [34] Hirohara, S., et al. Synthesis, photophysical properties and sugar-dependent in vitro photocytotoxicity of pyrrolidine-fused chlorins bearing S-glycosides. J. Photochem. Photobiol. B 97:1 (2009), 22–33.
35. [35] Ribó, J.M., et al. Aggregation in water solutions of tetrasodium diprotonated meso-tetrakis (4-sulfonatophenyl) porphyrin. Journal of the Chemical Society(6), 1994, 681–682 Chemical Communications.
36. [36] Hollingsworth, J.V., et al. Characterization of the self-assembly of meso-tetra(4-sulfonatophenyl)porphyrin (H(2)TPPS(4-)) in aqueous solutions. Biomacromolecules 13:1 (2012), 60–72.
37. [37] Rice, Z., Bergkvist, M., Adsorption characteristics of a cationic porphyrin on nanoclay at various pH. J. Colloid Interface Sci. 335:2 (2009), 189–195.
38. [38] Xiang, S., et al. Uptake mechanisms of non-viral gene delivery. J. Control. Release 158:3 (2012), 371–378.
39. [39] Aggarwal, L.P.F., Baptista, M.S., Borissevitch, I.E., Effects of NaCl upon TPPS4 triplet state characteristics and singlet oxygen formation. J. Photochem. Photobiol. A Chem. 186:2–3 (2007), 187–193.